Hepatitis & Liver Cirrhosis

Stem cells from bone marrow and cord blood are being investigated as possible treatments for cirrhosis. Click on the link provided to find out more about each trial. It remains too early to know which approach will be most suitable. We need evidence collected in clinical trials to determine if a proposed stem cell treatment is both safe and effective.

tagged as Hepatitis & Liver Cirrhosis

  • Autologous Bone Marrow Stem Cells Transplantation for Liver Cirrhosis Location: China
    Overview: This trial is exploring whether the patient’s own bone marrow can benefit patients with liver failure due to damage caused by Hepatitis B infection. The trial involves one group of participants being treated with stem cells obtained from their own bone marrow (interventional arm), and a second group receiving conventional treatment for this condition (control arm). The trial is being conducted at the 452 PLA Hospital in China's Sichuan Province and is expected to run to September 2015 by which time they aim to have treated a total of 100 participants. Participants will be monitored for changes in liver function and clinical evidence of improvement in neurological function (hepatic encephalopathy).
    Link to Clinical Registry
    Trial Design: Safety and Efficacy Study
    Status: Open - Recruiting
    Stem Cell: Adult Bone Marrow Stem Cells
  • Infusion Through Hepatic Artery in Portal Hypertension Surgery for the Treatment of Liver Cirrhosis Location: China
    Overview: This trial is being conducted at Wenzhou Medical College and seeks to investigate the role of the patient’s own stem cells in the treatment of liver cirrhosis. Participants will be divided into two groups. The treatment group will receive an infusion of their own bone marrow stem cells directly into the liver at the time of surgery, or a control group that will only have surgery to treat their cirrhosis. The bone marrow stem cells will be harvested from the participants at the beginning of the surgery. Participants will be monitored at regular intervals over an initial two year period and assessed for complications and improvements in liver function. The trial is expected to enrol 50 subjects between June 2010 and June 2014.
    Link to Clinical Registry
    Trial Design: Safety and Efficacy Study
    Status: Open - Recruiting
    Stem Cell: Adult Bone Marrow Stem Cells
  • Safety and Efficacy Study of Umbilical Mesenchymal Stem Cells for Liver Cirrhosis Location: China
    Overview: his trial is being conducted at five University Hospital Centres in China in association with a Chinese biotech, Alliancells Bioscience Corporation. The trial seeks to investigate the effect of donated umbilical cord blood on patients with liver cirrhosis. Participants will be divided into a control group where they will receive standard treatment, and a test group where they will receive four intravenous injections (IV injections) of donated cord blood over a period of one year. The participants will be monitored for three years for complications and for changes in liver function. The trial expects to enrol 320 participants by October 2015.
    Link to Clinical Registry
    Trial Design: Therapeutic intervention
    Status: Not yet started
    Stem Cell: Umbilical Cord Stem Cells
  • Autologous Bone Marrow Stem Cells in Patients with End Stage Liver Diseases Location: China
    Overview: This trial aims to investigate the safety and effectiveness of the patient's own bone marrow stem cells for end stage liver diseases. The trial is being conducted by the 105th PLA Hospital in Anhui Province and plans to enrol 100 patients with end stage liver failure. The subjects will be administered an intravenous (IV) infusion of their own bone marrow derived stem cells. Participants will be monitored for complications and for makers of liver failure. The trial commenced in February 2012.
    Link to Clinical Registry
    Trial Design: Therapeutic intervention
    Status: Open - Recruiting
    Stem Cell: Adult Bone Marrow Stem Cells
  • A Clinical Trial to Study the Safety and Efficacy of Stem Cells in Alcoholic Liver Cirrhosis Location: India
    Overview: This trial aims to assess the safety and effectiveness of donatd mesenchymal stem cells in patients with alcoholic liver cirrhosis. The trial is being conducted in 10 different centres throughout India in conjunction with Stempeutics Research Pvt. Ltd. The trial seeks to recruit 60 subjects by April 2014 with moderate to severe alcoholic liver cirrhosis. The participants will be randomised into three groups, each receiving a proprietary, donated mesenchymal stem cell preparation in either a low, intermediate or high dose. The stem cells will be injected directly into the hepatic artery with a catheter inserted through a percutaneous puncture of the femoral artery. Participants will be monitored for complications and assessed for liver function.
    Link to Clinical Registry
    Trial Design: Safety and Efficacy Study
    Status: Open - Recruiting
    Stem Cell: Stem Cells (unspecified)
  • Autologous Peripheral Blood Stem Cells in Patients with End Stage Liver Diseases Location: China
    Overview: This trial was conducted to evaluate the safety and effectiveness of using the patient's own blood stem cells in the treatment of end stage liver disease. This study was conducted between July 2005 and November 2012 at the Xijing Hospital in Shanxi province. Four hundred participants with end stage liver disease were allocated into either a treatment group that received an injection of their own stem cells collect from their peripheral blood, or a control group that received conventional treatment only. The participants were monitored for complications and improvements in liver function. The trial is now closed Results do not appear to have been published.
    Link to Clinical Registry
    Trial Design: Safety and Efficacy Study
    Status: Completed
    Stem Cell: Adult Bone Marrow Stem Cells
  • Difference in Efficacy Between Stem Cell Transplantation and Classical Therapy in Liver Cirrhosis Patients Location: China
    Overview: This trial aims to investigate the use of donated cord blood stem cells in the treatment of liver failure resulting from cirrhosis. The trial is being conducted by the General Hospital of Chinese Armed Police Forces and the Hebei Medical University First Hospital and expects to recruit 60 patients with severe to moderate hepatic failure/cirrhosis between November 2012 and July 2014. They propose to recruit 30 participants who will be randomly divided into two groups. One group will receive an infusion of mesenchymal stem cells obtained from donated umbilical cord blood. The second group will receive standard anti-viral treatment (lamuvidine and adefovir dipivoxil). Participants will be monitored for complications and changes in clinical condition.
    Link to Clinical Registry
    Trial Design: Safety and Efficacy Study
    Status: Open - Recruiting
    Stem Cell: Umbilical Cord Stem Cells
  • Umbilical Cord Mesenchymal Stem Cells Transplantation Combined with Plasma Exchange for Patients with Liver Failure Location: China
    Overview: This trial aims to investigate the safety and effectiveness of mesenchymal stem cells obtained from cord blood for patients with liver failure caused by the Hepatitis B Virus. The trial is being conducted by the Third Affiliated Hospital of the Sun Yat- Sen University in Guangdong and proposes to recruit 120 patients between November 2012 and March 2015. Participants will be randomly divided into one of four groups. The first group will receive only conventional treatment for liver failure including anti-viral therapy (control group). The second group will receive umbilical cord blood stem cells intravenously (IV) in addition to conventional therapy. The third group will receive conventional therapy and have plasma exchange. The fourth group will receive conventional therapy, umbilical cord blood stem cells and have plasma exchange therapy. Participants will be monitored for complications and changes in clinical condition.
    Link to Clinical Registry
    Trial Design: Safety and Efficacy Study
    Status: Not yet started
    Stem Cell: Umbilical Cord Stem Cells
  • Application of the Stem Cell Therapy in the End Stage Liver Disease and Assessment Its Consequences in the Quality of Live Style as Well as Development of HCC. Location: Egypt
    Overview: This observational study seeks to record the incidence of liver cancer in patients with infected with hepatitis C virus that have had stem cell therapy, compared to those who have only had conventional therapy. The study is being conducted at the University of Cairo and proposes to review 280 patients with Hepatitis C by end of December 2013. It is anticipated that half of the participants will have receive stem cell therapy. The incidence of liver cancer will be recorded as the primary outcome.
    Link to Clinical Registry
    Trial Design: Observational Study
    Status: Open - Recruiting
    Stem Cell: